Safety and performance of the resorbable magnesium scaffold,
Magmaris in a real world setting - First cohort subjects at 12-month follow-up
of the BIOSOLVE-IV registry
Michael Lee, MDQueen Elizabeth Hospital
Hong Kong SAROn behalf of the BIOSOLVE-IV investigators
Potential conflicts of interest
Michael Lee
Speaker's name : Michael Lee
☑ I do not have the potential conflicts of interest to declare.
Magmaris (DREAMS 2G)
Michael Lee
• 6-crown 2-link design
• 150 µm strut thickness
• 150 µm strut width
• Optimized scaffold design for
Higher bending flexibility
Higher acute radial force
Slower resorption rate: 95% at 12 months
• Sirolimus drug elution & PLLA (ORSIRO BIOlute coating)
• Tantalum radiopaque markers
• Gained CE mark in June 2016
Sirolimus + PLLA (BIOlute)
90-Day Faxitron, porcine explant
150 µm
150 µm
Registry Design
Design
• Prospective, multi-center (up to 120 sites in up to 30
countries), real world setting registry
Primary Endpoint
• Target Lesion Failure (TLF) at 12 months
Secondary Endpoints (at 6 months, 1-5 years)
• TLF*
• Clinically Driven TLR and TVR
• Cardiac Death
• Target Vessel MI
• Procedure and Device Success
• Scaffold thrombosis at 12 months (powered for
superiority of Magmaris compared to Absorb)
Coordinating Clinical Investigators
• S. Verheye, MD, Belgium – Europe
• M. Lee, MD, Hong Kong – Asia Pacific
2054 patients with
de novo coronary artery stenosis
6-month Clinical FUP
12-month Clinical FUP
24-month Clinical FUP
60-month Clinical FUP
36-month Clinical FUP
48-month Clinical FUP
*TLF: composite of target vessel myocardial
infarction, clinically driven TLR, cardiac death
and emergent CABG
Michael Lee
Enrollment & Registry Organization
• Data being presented for Cohort 1 (1075 subjects)
• Subjects were enrolled according to the consensus letter1, 4Ps and Instruction for Use (IFU)
• NSTEMI subjects included in BIOSOLVE-IV
• 4P Strategy
• Independent Clinical Events Committee: Adjudication of all ADE, SADE, USADE and endpoint related SAE
• Independent Core laboratory imaging analysis of endpoint related events
• 25 % source data verification
Patient & lesion selection
Proper scaffold sizing
Pre-dilatation for lesion
preparation
Post-dilatation
Michael Lee
1. Fajadet et al., EuroIntervention 2016; 12:828-833
Baseline Patient & Lesion Characteristics
Baseline Characteristics N (%)
Age (mean ± SD) 61.3 ± 10.5
Male 806 (75.0)
Hypertension 724 (67.3)
Hyperlipidemia 713 (66.3)
Smoking history 654 (61.1)
Diabetes mellitus 228 (21.2)
Insulin dependent 45 (19.7)
Non-Insulin dependent 183 (80.3)
History of MI 219 (20.4)
Previous percutaneous Intervention
287 (26.7)
NSTEMI 206 (19.2)
Lesion Location N (%)
LAD 561 (50.0)
LCX 213 (19.0)
RCA 333 (29.7)
Ramus intermedius 14 (1.2)
Lesion Characteristics* N (%)
Lesion length (mm ± SD) 14.9 ± 4.2
RVD (mm ± SD) 3.2 ± 0.3
AHA / ACC Lesion Class B2 / C 170 (15.2)
Calcification moderate / severe 82 (7.3)
Bifurcation lesions 57 (5.1)
Michael Lee
*Lesion characteristics are estimated by investigator
Target Lesion Failure out to 12 Months
Device success: 97.3% & Procedure success: 98.9%
• 1 Composite of cardiac death, target vessel myocardial infarction (TV-MI), clinically driven target lesion revascularization (CD-TLR) and emergent CABG. Peri-procedural MI according to SCAI definition and spontaneous MI according to the Extended Historical definition.
• All events have been adjudicated by an independent clinical event committee
0 30 180 365
Time to Event [days]
0
5
10
15
20
25
100
4.3% [95% CI: 3.2;5.7]
TLF
[%]1
Michael Lee
0.5% [95% CI: 0.2;1.1]
Secondary endpoints out to 12 Months
Michael Lee
0 30 180 365Time to Event [days]
0
5
10
15
20
25
100
Targ
et v
esse
l MI[
%]
0 30 180 365
Time to Event [days]
0
5
10
15
20
25
100
Car
dia
cD
eath
[%
]
0 30 180 365Time to Event [days]
0
5
10
15
20
25
100
Clin
ical
ly d
rive
n T
LR [
%]
1.1% [95% CI: 0.6;2.0]
3.9% [95% CI: 2.9;5.3]
0.2% [95% CI: 0.0;0.7]
4 out of 5 scaffold thrombosis cases had early
antiplatelet or anticoagulant interruption
after procedure
0 30 180 365
Time to Event [days]
0
5
10
15
20
25
100
Scaf
fold
th
rom
bo
sis
[%]
(def
init
e/p
rob
able
)1
Conclusions
BIOSOLVE-IV confirms low TLF rates (4.3% at 12-month) from
previous trials also in a real world setting with 115 centers in 25 countries
Excellent device success (97.3%) and procedure success (98.9%)
Very good safety profile of the scaffold up to 12-month
• 0.2% cardiac death
• 0.5% scaffold thrombosis
• 0.1% scaffold thrombosis rate excluding cases with early antiplatelet or anticoagulant interruption
Michael Lee